MagForce AG is a medical technology company specializing in nanotechnology, focused on the development and marketing of innovative cancer therapies. The company offers the NanoTherm therapy, a procedure for the focal treatment of brain tumors that is already approved in Europe. Additionally, a clinical study for the treatment of prostate cancer in the USA is in its final stage. The MagForce Group comprises several subsidiaries focused on the development, production, and distribution of NanoTherm technology.
Die nanobiotechnologische und medizintechnische Forschung und Entwicklung und Vermarktung von medizintechnischen Produkten sowie alle damit im Zusammenhang stehenden Geschäfte.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Berlin (Charlottenburg) Local Court, HRB 98748 (as of 30 October 2026)
| Name | Type | City |
|---|---|---|
| Ben Lipps | Vorstand | Incline Village/Nevada/ U.S.A. |
| Christian von Volkmann | Vorstand | Berlin |
Source: German Commercial Register (Handelsregister) Berlin (Charlottenburg) Local Court, HRB 98748 (as of 30 October 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2021 | €351,984 | -€10,572,408 | €62,829,449 | 32 |
| 2020 | €839,933 | -€8,728,852 | €65,591,666 | 28 |
| 2019 | €67,200 | — | €36,659,903 | 26 |
| 2018 | €716,118 | — | €37,134,110 | 26 |
| 2017 | €473,777 | -€7,231,283 | €22,032,190 | 24 |
| 2016 | €473,777 | -€7,231,283 | €20,278,128 | 29 |
| 2015 | €2,575,885 | -€1,546,768 | €24,858,258 | 23 |
| 2014 | €0 | -€1,008,186 | €28,706,646 | 22 |
| 2013 | — | -€1,627,554 | €17,726,656 | — |
| 2012 | ≤ €12M1 | -€5,717,974 | €19,591,106 | — |
1 Small companies are not required to publish a profit-and-loss statement (§ 326 (1) HGB). The figure shown is the statutory ceiling under § 267 HGB where the balance-sheet total makes it binding — a company may exceed at most one of the three size criteria.
Sign in to download data
Source: German Commercial Register (Handelsregister) Berlin (Charlottenburg) Local Court, HRB 98748 (as of 30 October 2026)
TETEC Tissue Engineering Technologies AG
Reutlingen · Forschung und Entwicklung im Bereich Biotechnologie
Luye Pharma AG
Miesbach · Herstellung von pharmazeutischen Spezialitäten und sonstigen pharmazeutischen Erzeugnissen
VDI/VDE Innovation + Technik GmbH
Berlin · Forschung und Entwicklung im Bereich Rechts-, Wirtschafts- und Sozialwissenschaften sowie im Bereich Sprach-, Kultur- und Kunstwissenschaften
| Cost type | Amount | Share |
|---|---|---|
| Personnel Costs | €3,984,249 | 41.4% |
| Material Costs | €918,746 | 9.5% |
| Depreciation | €1,788,245 | 18.6% |
| Interest & Similar | €2,940,656 | 30.5% |
